| Exclusion Criteria: | 1) Patients with a concomitant malignancy other than non-melanoma skin cancer. With the exception of non-melanoma skin cancer, patients with a prior invasive malignancy who have been disease-free for < 5 years or who received prior chemotherapy for that malignancy.
2) Patients in whom pathological confirmation and Estrogen Receptor (ER)/Progesterone Receptor (PR) status of the tumor is not obtainable.
3) Patients for whom radiation therapy is planned during or after study chemotherapy prior to demonstrated progression.
4) Patients with comcomitant medical illness such as serious uncontrolled infection, uncontrolled angina or serious peripheral neuropathy which, in the opinion of the treating physician, make the treatments prescribed on this study unreasonably hazardous for the patient.
5) Patients with third-degree or complete heart block are not eligible unless a pacemaker is in place. Patients on medications which alter cardiac conduction, such as digitalis, beta blockers, or calcium channel blockers, or who have other conduction abnormalities or cardiac dysfunction may be placed on study at the discretion of the investigator.
6) Patients with history of myocardial infarct within 6 months before enrollment, New York Heart Association (NYHA) Class II or greater heart failure or symptoms suspicious for congestive heart failure are not eligble unless a lef ventricular ejection fraction in the past 6 months is documented to be 50% or greater. Patients who have had a LVEF (performed for any reason) of less than 50% in the past 6 months are ineligible.
7) Patients whose circumstances will not permit study completion or adequate follow-up.
8) Patients who are sensitive to E.Coli-derived drug preparations.
9) Patients with uterine carcinosarcoma or other non-epithelial uterine malignancies. |